DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94
Small · 2023-08 · 19 (35)
DOI: 10.1002/smll.202300403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 27.04.2023. Verfasst von Mengyuan Zhou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, P. R. China. Hauptthemen laut MEDLINE: Nanocapsules, Brain Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Receptor‐mediated vesicular transport has been extensively developed to penetrate the blood‐brain barrier (BBB) and has emerged as a class of powerful brain‐targeting delivery technologies. However, commonly used BBB receptors such as transferrin receptor and low‐density lipoprotein receptor‐related protein 1, are also expressed in normal brain parenchymal cells and can cause drug distribution in normal brain tissues and subsequent neuroinflammation and cognitive impairment. Here, the endoplasmic reticulum residing protein GRP94 is found upregulated and relocated to the cell membrane of both BBB endothelial cells and brain metastatic breast cancer cells (BMBCCs) by preclinical and clinical investigations. Inspired by that Escherichia coli penetrates the BBB via the binding of its outer membrane proteins with GRP94, avirulent DH5α outer membrane protein‐coated nanocapsules (Omp@NCs) are developed to cross the BBB, avert normal brain cells, and target BMBCCs via recognizing GRP94. Embelin (EMB)‐loaded Omp@EMB specifically reduce neuroserpin in BMBCCs, which inhibits vascular cooption growth and induces apoptosis of BMBCCs by restoring plasmin. Omp@EMB plus anti‐angiogenic therapy prolongs the survival of mice with brain metastases. This platform holds the translational potential to maximize therapeutic effects on GRP94‐positive brain diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Neuropsychiatric Diseases, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, P. R. China.
- MJiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, 215123, P. R. China.
- Department of Neurosurgery, The Second Affiliated Hospital of Soochow University, Soochow University, Suzhou, 215004, P. R. China.
- School of Life Science, Anhui Medical University, Hefei, 230032, P. R. China.
- National Engineering Research Centre of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University, Chongqing, 400038, P. R. China.
ORCID-Profile: Liang Han
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, M., Chen, H., Zeng, Y., Lv, Z., Hu, X., Tong, Y., Wang, P., Zhao, M., Mu, R., Yu, J., Chen, Y., Wei, L., Gu, J., Lan, Q., Zhen, X., & Han, L. (2023). DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94. Small, 19(35). https://doi.org/10.1002/smll.202300403
Vancouver
Zhou M, Chen H, Zeng Y, Lv Z, Hu X, Tong Y, et al. DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94. Small. 2023;19(35). doi:10.1002/smll.202300403
BibTeX
@article{Zhou2023,
author = {Zhou, Mengyuan and Chen, Haiyan and Zeng, Yuteng and Lv, Ziyan and Hu, Xiaoxiao and Tong, Yang and Wang, Pan and Zhao, Mei and Mu, Rui and Yu, Ju and Chen, Yanming and Wei, Lin and Gu, Jiang and Lan, Qing and Zhen, Xuechu and Han, Liang},
title = {DH5α Outer Membrane‐Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94},
journal = {Small},
year = {2023},
volume = {19},
number = {35},
doi = {10.1002/smll.202300403}
}
EUVIMED